TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Body Weight at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With at Least One Solicited Injection Site Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One Solicited Systemic Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: vascular duplex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: serum lncRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of student TDV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in hyper polarized MRI xenon-129 assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in child Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Oswestry Low Back Pain Disability Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Patients With Index Event Safety Outcomes (Ongoing/Resolved/Deceased) at Time of Hospital Discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Receiving Different Types of Interventions to Stop Index Events Until Hospital Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Bleeding Types and Anatomic Locations of the Index Event at Time of ED/ER Presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Levels of estrogens and catechol estrogen metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of CE-glutathione conjugates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of CE-DNA adducts (N3Ade and N7Gua)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Spontaneous ongoing pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETDRS Visual Acuities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCT Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Initial Claudication Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Requirement of Intensive Care Unit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of successful prevention of CSF leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Teeth Root length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root resorption lacunae number and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BSS (Bronchitis Severity Score) score variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Testosterone <0.5 Nanogram/Milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction rate of diabetic foot ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in mean Hepatitis B Virus (HBV) DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed the Explore Stage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Completed the Build Stage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Completed the Mobilize Stage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Completed the Quit Stage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Completed the Secure Stage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Variation in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Morphine Milligrams at 72 hours post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest dose tolerated
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of MDC product injection
Endpoint domain: Adverse events/effects
Primary endpoint: TOF-PTC value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Neuropsychiatric Inventory (NPI) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine Cotinine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: death from AAS
Endpoint domain: Mortality/survival
Primary endpoint: coagulopathy rTQ > 1.2 incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients Experiencing Decline in Prostate-specific Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain Relief response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory nutritional state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 12-month conversion rate
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence-free rate (RFR)
Endpoint domain: Mortality/survival
Primary endpoint: rate of good quality embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall best response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAM-ICU scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of AMI patients achieving target LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: safety and tolerability as assessed by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of plasma activin A (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of plasma follistation (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of plasma myostatin (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in 12-lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total number of MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Fibrin changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tacrolimus trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tacrolimus dosage (week 12 compared to week 24)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients reporting grade 2 or more xerostomia
Endpoint domain: Adverse events/effects
Primary endpoint: plasma concentration in fasted study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma concentration in fed study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gene Expression Associated with Psychological Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No evidence of disease progression at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Words Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Postpartum depression measured by EPDS scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical outcome (NDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtlast (Area Under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients Who Experienced At Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall patient's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in concentration of serum brain-derived neurotropic factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median Subject Time Spent on Cardiopulmonary Cross Clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median Amount of Time Subject Spent on Cardiopulmonary Bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Surviving at Six Months
Endpoint domain: Mortality/survival
Primary endpoint: Safety of initial antibiotic treatment strategy
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Amifostine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-donor T-cell alloresponses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in waist and hip circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of volunteers reaching day 21 post-infection without or with a delayed onset of parasitemiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Confidence in ability to do shared decision making
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinician satisfaction with encounter
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with encounter
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse event of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Intake at ad-libitum dinner
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIEF Erectile Function Domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in genetic or protein markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of rPPG heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of rPPG oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of rPPG respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in SLE Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or recovery
Endpoint domain: Mortality/survival
Primary endpoint: Device usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: average time needed to fall asleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Pathologic Stage Less Than or Equal to ypT2N0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain Treatment-VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence free at 3 year follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients presenting dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of gastric intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive identification of hypermethylated genes for CIN grade 3 or invasive cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk assessment of developing CIN3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to reach platelet counts ≥20,000/µl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Classified as Having High Sedentary Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Classified as Having Low Moderate-to-vigorous Intensity Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative and Postoperative Transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Fugl Meyer assessment of paretic upper limb motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: IUGR development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall hematological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Groningen Activity Restriction Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in MADRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Serum Phosphorus Levels Above LLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Root Roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smear Layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unwanted effects of therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline miccional emergency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in barrier pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of vertebral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to reach the target temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NSE as a parameter for cerebral damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Continuous complete response (CCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LNG pharmacokinetic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cervical mucus changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Movement Motivation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Interleukins concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in ADAS-Cog11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete Cure of Onychomycosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Duration of insensitivity towards cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale (VAS) Score for Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC VAS Pain Subscale Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence rate of irreversible graft dissociation or rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Secondary stroke prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual motor power testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of moderate or severe neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total 24 h Piritramide consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Vital Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Personal and Social Performance (PSP) Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Presence of CRE in anal swab or stool culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in Palliative Care Overall
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Assessment of Pain Management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospice Utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: PaCO2 (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Number of Eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: median nerve sensory conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Yale-Brown Obsessive Compulsive Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pre- and Post-phosphocreatine Relaxation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of myPAtHS exercise sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent doing the myPAtHS exercise programme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: developmental status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with clinically diagnosed and treated UTI
Endpoint domain: Adverse events/effects
Primary endpoint: Anticoagulation compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite Rate of Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Daytime ambulatory mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need to wear a wig or other head covering
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Recurrence of Intestinal Metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in global health status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean weight-for-length z-score at 15 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biodistribution of radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics in blood and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time for appropriate adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapy efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Insecurity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with treatment stop seizures attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Proportion of Patients With HBsAg Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heart rate under exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: non-inferiority of talc pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2* signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial Spin Labeled (ASL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes